The contribution of white matter changes to clinical phenotype in progressive supranuclear palsy

被引:1
作者
Tepedino, Maria Francesca [1 ]
Diana, Francesco [2 ,3 ]
Abate, Filomena [1 ]
Avallone, Anna Rosa [1 ]
Caterino, Miriam [1 ]
Erro, Roberto [1 ]
Pellecchia, Maria Teresa [1 ]
Manara, Renzo [4 ]
Barone, Paolo [1 ]
Picillo, Marina [1 ]
机构
[1] Univ Salerno, Ctr Neurodegenerat Dis CEMAND, Dept Med Surg & Dent, Scuola Med Salernitana, Via Allende, I-84081 Baronissi, Salerno, Italy
[2] Azienda Osped Univ San Giovanni Dio & Ruggi Aragon, Dept Neuroradiol, Salerno, Italy
[3] Vall dHebron Univ Hosp, Intervent Neurol Dept, Barcelona, Spain
[4] Univ Padua, Dept Neurosci, Neuroradiol Unit, I-35128 Padua, Italy
关键词
Progressive supranuclear palsy; Phenotype; Vascular; MRI; PARKINSONS-DISEASE; RATING-SCALE; RISK-FACTORS; DEMENTIA; HYPERINTENSITIES; LESIONS; MRI;
D O I
10.1007/s00415-024-12662-0
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
White matter hyperintensities (WMH) are considered magnetic brain imaging (MRI) biomarkers of cerebral small vessel disease but their clinical role in neurodegenerative-related disorders is poorly understood. This study describes the distribution of WMH on brain MRI in Progressive Supranuclear Palsy (PSP) in comparison with Parkinson's disease (PD) and explores their possible impact on disease's features. Sixty PSP and 33 PD patients were included. Motor symptoms, cardiovascular risk factors and the age-related white matter changes (ARWMC) score was computed to rate WMH for both groups. Pearson's correlation and linear or logistic regression analysis were used to check for relationships between ARWMC and PSP clinical scores. The mean (standard deviation) ARWMC total score in the PSP cohort was 4.66 (3.25). Any degree of WMH was present in 68% of PSP (ARWMC +). Compared to ARWMC-, ARWMC + did not have greater disease severity or more cardiovascular risk factors. WMH were frequently localized in fronto-parietal lobes and were mild in severity. Linear regression analysis showed that ARWMC total score was related to the PSP-rating scale, irrespective of age, disease duration and the Charlson modified comorbidity index. Logistic regression analysis confirmed that ARWMC total score was related to the use of wheelchair, irrespective of above-mentioned covariates. Vascular risk factors as well as severity and distribution of WMH did not have an impact on the PSP phenotype. No differences were found with PD patients. Our results suggest that WMH in PSP might be markers of neurodegenerative-related pathology rather than being simple expression of atherosclerotic cerebrovascular changes.
引用
收藏
页码:6866 / 6875
页数:10
相关论文
共 36 条
  • [1] White matter lesions in Parkinson disease
    Bohnen, Nicolaas I.
    Albin, Roger L.
    [J]. NATURE REVIEWS NEUROLOGY, 2011, 7 (04) : 229 - 236
  • [2] Cerebral small vessel disease: neuroimaging markers and clinical implication
    Chen, Xiaodong
    Wang, Jihui
    Shan, Yilong
    Cai, Wei
    Liu, Sanxin
    Hu, Mengyan
    Liao, Siyuan
    Huang, Xuehong
    Zhang, Bingjun
    Wang, Yuge
    Lu, Zhengqi
    [J]. JOURNAL OF NEUROLOGY, 2019, 266 (10) : 2347 - 2362
  • [3] White matter hyperintensities, cerebrospinal amyloid-β and dementia in Parkinson's disease
    Compta, Yaroslau
    Buongiorno, Mariateresa
    Bargallo, Nuria
    Valldeoriola, Francesc
    Munoz, Esteban
    Tolosa, Eduardo
    Rios, Jose
    Camara, Ana
    Fernandez, Manel
    Marti, Maria J.
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2016, 367 : 284 - 290
  • [4] The neuropsychiatric inventory: Assessing psychopathology in dementia patients
    Cummings, JL
    [J]. NEUROLOGY, 1997, 48 (05) : S10 - S16
  • [5] Cortical thickness in de novo patients with Parkinson disease and mild cognitive impairment with consideration of clinical phenotype and motor laterality
    Danti, S.
    Toschi, N.
    Diciotti, S.
    Tessa, C.
    Poletti, M.
    Del Dotto, P.
    Lucetti, C.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 (12) : 1564 - 1572
  • [6] Dickson DW, 1999, J NEUROL, V246, P6
  • [7] How to weight chronic diseases in multimorbidity indices? Development of a new method on the basis of individual data from five population-based studies
    Diederichs, Claudia P.
    Wellmann, Juergen
    Bartels, Dorothee B.
    Ellert, Ute
    Hoffmann, Wolfgang
    Berger, Klaus
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 2012, 65 (06) : 679 - 685
  • [8] Neuropathology of white matter changes in Alzheimer's disease and vascular dementia
    Englund, E
    [J]. DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 1998, 9 : 6 - 12
  • [9] A clinical rating scale for progressive supranuclear palsy
    Golbe, Lawrence I.
    Ohman-Strickland, Pamela A.
    [J]. BRAIN, 2007, 130 : 1552 - 1565
  • [10] The comorbidity and co-medication profile of patients with progressive supranuclear palsy
    Greten, Stephan
    Wegner, Florian
    Jensen, Ida
    Krey, Lea
    Rogozinski, Sophia
    Fehring, Meret
    Heine, Johanne
    Doll-Lee, Johanna
    Poetter-Nerger, Monika
    Zeitzschel, Molly
    Hagena, Keno
    Pedrosa, David J.
    Eggers, Carsten
    Buerk, Katrin
    Trenkwalder, Claudia
    Claus, Inga
    Warnecke, Tobias
    Suess, Patrick
    Winkler, Juergen
    Gruber, Doreen
    Gandor, Florin
    Berg, Daniela
    Paschen, Steffen
    Classen, Joseph
    Pinkhardt, Elmar H.
    Kassubek, Jan
    Jost, Wolfgang H.
    Toenges, Lars
    Kuehn, Andrea A.
    Schwarz, Johannes
    Peters, Oliver
    Dashti, Eman
    Priller, Josef
    Spruth, Eike J.
    Krause, Patricia
    Spottke, Annika
    Schneider, Anja
    Beyle, Aline
    Kimmich, Okka
    Donix, Markus
    Haussmann, Robert
    Brandt, Moritz
    Dinter, Elisabeth
    Wiltfang, Jens
    Schott, Bjoern H.
    Zerr, Inga
    Baehr, Mathias
    Buerger, Katharina
    Janowitz, Daniel
    Perneczky, Robert
    [J]. JOURNAL OF NEUROLOGY, 2024, 271 (02) : 782 - 793